Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
STAT2h
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
FierceBiotech2h
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo.
Novo Nordisk stock falls over oral weight-loss drug data
Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...
The Pharma Letter1h
Novo Nordisk’s obesity newcomer monlunabant heads into Phase IIb
Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.
Novo Nordisk shares fall after Monlunabant phase 2a trial results; Viking jumps
Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesity drug, monlunabant.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...
NBC New York9d
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
BioSpace2h
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...